Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C53H102N2O20P2 |
Molecular Weight | 1149.3259 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 12 / 12 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCC[C@@H](O)CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]2NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)O[C@H]1COP(O)(O)=O
InChI
InChIKey=UUVVKHSZRKZOGM-CUECXTGJSA-N
InChI=1S/C53H102N2O20P2/c1-4-7-10-13-16-19-22-25-28-31-39(57)34-44(58)54-47-42(38-71-76(64,65)66)73-43(49(61)50(47)62)37-70-53-48(51(63)52(41(36-56)74-53)75-77(67,68)69)55-45(59)35-40(32-29-26-23-20-17-14-11-8-5-2)72-46(60)33-30-27-24-21-18-15-12-9-6-3/h39-43,47-53,56-57,61-63H,4-38H2,1-3H3,(H,54,58)(H,55,59)(H2,64,65,66)(H2,67,68,69)/t39-,40-,41-,42+,43-,47+,48-,49-,50-,51-,52-,53-/m1/s1
Defoslimod is an analog of lipopolysaccharide endotoxin-derived lipid A obtained from E. coli, developed as an immunomodulatory adjuvant and an immunotherapeutic agent for the treatment of cancer. Defoslimod acts as an agonist of Toll-like receptor (TLR) 2/4. In a phase 1 clinical study in patients with solid tumors, conducted in 2007, defoslimod was administered as an intravenous infusion. The therapy was well tolerated at biologically active concentrations, with 3 patients of 17 exhibited disease stabilization with a mean duration of 4 months. No further development of the drug was reported.
Approval Year
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C169880
Created by
admin on Fri Dec 15 19:37:50 GMT 2023 , Edited by admin on Fri Dec 15 19:37:50 GMT 2023
|
PRIMARY | |||
|
HC3530GGGG
Created by
admin on Fri Dec 15 19:37:50 GMT 2023 , Edited by admin on Fri Dec 15 19:37:50 GMT 2023
|
PRIMARY | |||
|
C400105
Created by
admin on Fri Dec 15 19:37:50 GMT 2023 , Edited by admin on Fri Dec 15 19:37:50 GMT 2023
|
PRIMARY | |||
|
7734
Created by
admin on Fri Dec 15 19:37:50 GMT 2023 , Edited by admin on Fri Dec 15 19:37:50 GMT 2023
|
PRIMARY | |||
|
171092-39-0
Created by
admin on Fri Dec 15 19:37:50 GMT 2023 , Edited by admin on Fri Dec 15 19:37:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105854
Created by
admin on Fri Dec 15 19:37:50 GMT 2023 , Edited by admin on Fri Dec 15 19:37:50 GMT 2023
|
PRIMARY | |||
|
56841121
Created by
admin on Fri Dec 15 19:37:50 GMT 2023 , Edited by admin on Fri Dec 15 19:37:50 GMT 2023
|
PRIMARY | |||
|
300000042682
Created by
admin on Fri Dec 15 19:37:50 GMT 2023 , Edited by admin on Fri Dec 15 19:37:50 GMT 2023
|
PRIMARY |
ACTIVE MOIETY